natgillin/translations-raw huggingface dataset:
The total excreted amount of thiotepa and its identified metabolites accounts for 54-100% of the total alkylating activity, indicating the presence of other alkylating metabolites. 
Skupna izločena količina tiotepe in njenih ugotovljenih metabolitov predstavljajo 54-100 % vse alkilirajoče aktivnosti, kar kaže na prisotnost še drugih alkilirajočih metabolitov.
TEPADINA can be used in adults and children and adolescents. 
Zdravilo TEPADINA se uporablja pri odraslih, otrocih in mladostnikih.
Your doctor will monitor your blood counts and liver enzymes regularly to detect and manage these events. 
- zapleti pri dihanju Zdravnik bo redno nadziral vašo krvno sliko in jetrne encime za odkrivanje in obvladovanje teh učinkov.
For instructions on reconstitution and further dilution prior to administration, see section 6.6. 
Za dodatna navodila glede rekonstitucije in nadaljnjega razredčevanja pred dajanjem glejte poglavje 6.6.
Patients who have received prior radiation therapy, greater than or equal to three cycles of chemotherapy, or prior progenitor cell transplant may be at an increased risk of hepatic veno-occlusive disease (see section 4.8). 
Bolniki, ki so prejeli predhodno zdravljenje z obsevanjem, daljše ali enako trem ciklom kemoterapije, ali predhodno presaditev matičnih celic, so lahko bolj izpostavljeni venookluzivni bolezni jeter (glejte poglavje 4.8).
Thiotepa was shown to be genotoxic in vitro and in vivo, and carcinogenic in mice and rats. 
Tiotepa se je izkazala za genotoksično in vitro in in vivo ter karcinogeno pri miših in podganah.
In some cases, relapse rates lower than 40% have also been reported at 5 years and 10 years. 
V nekaterih primerih so poročali tudi o stopnjah ponovitve, nižjih od 40 %, za obdobje pet in deset let.
GvHD (graft versus host disease): all conditioning treatments evaluated assured a low incidence of acute GvHD grade III-IV (from 4% to 24%). 
GvHD (reakcija presadka proti gostitelju): vsa ocenjena pripravljalna zdravljenja so zagotovila majhen pojav akutne GvHD stopnje III-IV (od 4 do 24 %).
(10 mg/kg), during the time of the entire conditioning treatment. 
(42 mg/kg) v času celotnega pripravljalnega zdravljenja.
Do not use TEPADINA after the expiry date which is stated on the carton and vial label, after EXP. 
Tega zdravila ne smete uporabljajti po datumu izteka roka uporabnosti, ki je naveden na škatli in nalepki na viali, poleg oznake „EXP“.
The infusion solution must be administered to patients using an infusion set equipped with a 0.2 µm in-line filter. 
Raztopino za infudiranje bolnikom je treba odmeriti s pomočjo infuzijskega kompleta, opremljenega z linijskim filtrom, velikosti 0,2 µm.
The most important adverse reactions expected in case of overdose is myeloablation and pancytopenia. 
Najpomembnejša neželena učinka v primeru prevelikega odmerjanja sta mieloablacija in pancitopenija.
Alkylating chemotherapeutic agents, including thiotepa, inhibit plasma pseudocholinesterase by 35% to 70%. 
Alkilirajoči citostatiki, vključno s tiotepo, zavirajo plazemsko psevdoholinesterazo za 35 do 70 %.
Concomitant use with live attenuated vaccines (except yellow fever vaccines), phenytoin and fosphenytoin is not recommended (see section 4.5). 
Sočasna uporaba z živimi atenuiranimi cepivi (razen cepivi za rumeno mrzlico), fenitoinom in fosfenitoinom ni priporočljiva (glejte poglavje 4.5).
Pulmonary arterial hypertension 
Pljučna arterijska hipertenzija
Thiotepa undergoes rapid and extensive hepatic metabolism and metabolites could be detected in urine within 1 hour after infusion. 
Tiotepa se v jetrih hitro in v veliki meri presnovi, metabolite je v urinu mogoče zaznati v eni uri po infundiranju.
What TEPADINA is and what it is used for 
Kaj je zdravilo TEPADINA in za kaj ga uporabljamo
Phenytoin: risk of exacerbation of convulsions resulting from the decrease of phenytoin digestive absorption by cytotoxic medicinal product or risk of toxicity enhancement and loss of efficacy of the cytotoxic medicinal product due to increased hepatic metabolism by phenytoin. 
Fenitoin: tveganje poslabšanja konvulzij zaradi slabše absorpcije fenitoina s citotoksičnim zdravilom ali tveganje povečane toksičnosti in izgube učinkovitosti citotoksičnega zdravila zaradi povečane jetrne presnove s fenitoinom.
Thiotepa appears to be metabolised via CYP2B6 and CYP3A4. 
Zdi se, da se tiotepa presnavlja preko CYP2B6 in CYP3A4.
Thiotepa is a weak inhibitor for CYP2B6, and may thereby potentially increase plasma concentrations of substances metabolised via CYP2B6, such as ifosfamide, tamoxifen, bupropion, efavirenz and cyclophosphamide. 
Tiotepa je šibak zaviralec CYP2B6 in lahko zato v plazmi potencialno zviša koncentracije snovi, ki se presnavljajo s CYP2B6, kot so ifosfamid, tamoksifen, bupropion, efavirenz in ciklofosfamid.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal. 
• Redno posodobljena poročila o varnosti zdravila (PSUR) Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7)
Severe granulocytopenia, thrombocytopenia, anaemia or any combination thereof may develop. 
Razvijejo se lahko huda granulocitopenija, trombocitopenija, anemija ali kombinacija teh.
No conventional acute and repeat dose toxicity studies were performed. 
Običajne študije akutne toksičnosti in toksičnosti pri ponavljajočih se odmerkih niso bile izvedene.
Mental disorder due to a general medical condition 
Psihiatrične motnje duševne motnje duševne motnje zaradi splošnega zdravstvenega stanja
These include infection and Graft-versus host disease (GvHD) which, although not directly related, were the major causes of morbidity and mortality, especially in allogeneic HPCT. 
Posledice zajemajo okužbo in reakcijo presadka proti gostitelju (GVHD: Graft-versus host disease), ki sta bili, čeprav ne neposredno povezani, glavna vzroka obolevnosti in umrljivosti, zlasti pri alogenski PKMC.
The identified metabolites TEPA, monochlorotepa and thiotepa-mercapturate are all excreted in the urine. 
Ugotovljeni metaboliti TEPA, monoklorotepa in tiotepa-merkapturat se vsi izločajo v urinu.
Engraftment: It has been achieved with all evaluated conditioning regimens including thiotepa with a success rate of 96% - 100%. 
Sprejem presadka: dosežen je bil pri vseh ocenjenih režimih pripravljalnega zdravljenja s tiotepo, s stopnjo uspešnosti 96 do 100 odstotkov.
Contents of the pack and other information What TEPADINA contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo TEPADINA
Due to its lack of extramedullary toxicity despite dose escalation beyond myelotoxic doses, thiotepa has been used for decades in combination with other chemotherapy medicinal products prior to autologous and allogeneic HPCT. 
Zaradi netoksičnosti izven kostnega mozga kljub stopnjevanju odmerka, ki presega mielotoksične odmerke, se tiotepa že desetletja uporablja v kombinaciji z drugimi kemoterapevtiki pred avtologno in alogensko PKMC.
Only colourless solutions, without any particulate matter, must be used. 
Uporabijo se lahko le brezbarvne raztopine, brez vidnih delcev.
What you need to know before you use TEPADINA Do not use TEPADINA 
Kaj morate vedeti, preden boste uporabili zdravilo TEPADINA Ne uporabljajte zdravila TEPADINA
TEPADINA is for single use only. 
Zdravilo TEPADINA je samo za enkratno uporabo.
Cases of leukoencephalopathy have been observed following treatment with thiotepa in adult and paediatric patients with multiple previous chemotherapies, including methotrexate and radiotherapy. 
Primeri levkoencefalopatije po zdravljenju s tiotepo so bili opaženi pri odraslih in otrocih, ki so v preteklosti prejeli več kemoterapij, vključno z metotreksatom in radioterapijo.
As thiotepa and its metabolites are poorly excreted in the urine, dose modification is not recommended in patients with mild or moderate renal insufficiency. 
Ker se tiotepa in njeni presnovki slabo izločajo z urinom, prilagoditev odmerka ni potrebna pri bolnikih z blago ali srednjo ledvično insuficienco.
As a precautionary measure, women must not breast-feed during treatment with TEPADINA. 
Iz previdnostnih razlogov ženske med zdravljenjem z zdravilom TEPADINA ne smejo dojiti.
TEPADINA may have major influence on the ability to drive and use machines. 
Zdravilo TEPADINA ima lahko pomemben vpliv na sposobnost vožnje in upravljanja s stroji.
Live attenuated vaccines (except yellow fever): risk of systemic, possibly fatal disease. 
Živa atenuirana cepiva (razen cepiva proti rumeni mrzlici): tveganje sistemske, lahko tudi smrtno nevarne bolezni.
Due to its highly myeloablative characteristics, thiotepa enhances recipient immunosuppression and myeloablation, thus strengthening engraftment; this compensates for the loss of the GvHD-related GvL effects. 
Zaradi močnih mieloablativnih lastnosti tiotepa okrepi imunosupresijo in mieloablacijo prejemnika, zaradi česar je sprejem presadka okrepljen; to nadomesti izgubo učinka presadka proti levkemiji (učinek GvL), povezanega z GvHD.
Not known: frequency cannot be estimated from the available data - increased blood pressure in the arteries (blood vessels) of the lungs (pulmonary arterial hypertension) - severe skin damage (e.g. severe lesions, bullae, etc.) potentially involving the full body surface which can be even life-threatening - damage to a component of the brain (the so called white matter) which can be even lifethreatening (leukoencephalopathy). 
Neznana pogostnost: pogostnosti ni mogoče oceniti iz razpoložljivih podatkov - zvišan krvni tlak v arterijah (krvnih žilah) v pljučih (pljučna arterijska hipertenzija) - huda poškodba kože (npr. hude razjede, mehurji itd.), ki lahko vključuje celotno površino telesa in je lahko celo življenjsko nevarna - poškodba dela možganov (t. i. bela možganovina), ki je lahko celo življenjsko nevarna (levkoencefalopatija).
Due to its pharmacological properties and its potential toxicity for breast-fed newborns/infants, breast-feeding is contraindicated during treatment with thiotepa. 
Zaradi farmakoloških lastnosti in potencialne toksičnosti za dojene novorojenčke/otroke je dojenje kontraindicirano med zdravljenjem s tiotepo.
The volume of distribution of thiotepa is large and it has been reported as ranging from 40.8 l/m2 to 75 l/m2, indicating distribution to total body water. 
Volumen porazdelitve tiotepe je velik in po poročanju niha med 40,8 l/m2 do 75 l/m2, kar kaže na porazdelitev v vse tekočine v telesu.
TEPADINA should be aseptically administered as a 2-4 hours infusion under room temperature (about 25°C) and normal light conditions. 
Zdravilo TEPADINA se daje aseptično kot 2- do 4-urna infuzija pri sobni temperaturi (okrog 25 °C) in pod običajnimi svetlobnimi pogoji.
Pharmacotherapeutic group: Antineoplastic agents, Alkylating Agents, ATC code: L01AC01 
Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe (citostatiki), alkilirajoči citostatiki, oznaka ATC: L01AC01
It is unknown whether thiotepa is excreted in human milk. 
Ni znano, ali se tiotepa izloča v materino mleko.
Solid tumours 
Čvrsti tumorji
Each carton contains 1 vial. 
Pakiranje vsebuje 1 vialo.
TEPADINA is indicated, in combination with other chemotherapy medicinal products: 
Zdravilo TEPADINA se uporablja v kombinaciji z drugimi kemoterapevtiki:
Intravenous use, after reconstitution and dilution. 
intravenska uporaba, po rekonstituciji in redčenju
The conditioning treatment must provide cytoreduction and ideally disease eradication. 
Pripravljalno zdravljenje mora zagotoviti citoredukcijo in, v idealnih okoliščinah, izkoreninjenje bolezni.
• when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients. 
• ko je kemoterapija z visokimi odmerki s podporo PKMC primerna za zdravljenje čvrstih tumorjev pri odraslih in pediatričnih bolnikih.
After reconstitution, use within 8 hours when stored in a refrigerator. 
Po rekonstituciji uporabite v 8 urah, če je zdravilo shranjeno v hladilniku.
After dilution, use within 24 hours when stored in a refrigerator. 
Po redčenju uporabite v 24 urah, če je zdravilo shranjeno v hladilniku.
For storage conditions of the reconstituted and diluted medicinal product, see section 6.3. 
Za pogoje shranjevanja rekonstituiranega zdravila in zdravila po redčenju glejte poglavje 6.3.
Considering that all patients suffer of recurrence or poor prognosis solid tumours, these rates support the efficacy of conditioning regimens based on thiotepa. 
Ob upoštevanju, da je pri vseh bolnikih možna ponovitev čvrstih tumorjev ali gre za čvrste tumorje s predvidenim slabim izidom, te stopnje potrjujejo učinkovitost režimov pripravljalnega zdravljenja na osnovi tiotepe.
Posology in paediatric patients 
Odmerjanje pri pediatričnih bolnikih
The most frequently adverse reactions reported in the different conditioning treatments including thiotepa are: infections, cytopenia, acute GvHD and chronic GvHD, gastrointestinal disorders, haemorrhagic cystitis, mucosal inflammation. 
Najpogostejše neželene reakcije pri različnih pripravljalnih zdravljenjih, vključno s tiotepo, o katerih so poročali, so: okužbe, citopenija, akutna GvHD in kronična GvHD, bolezni prebavil, hemoragični cistitis, vnetje sluznice.
All transfer procedures require strict adherence to aseptic techniques, preferably employing a vertical laminar flow safety hood. 
Pri vseh prenosih morate strogo upoštevati aseptične pogoje in po možnosti uporabiti zaščitno komoro z navpičnim laminarnim tokom zraka.
When treating such patients it is recommended that serum transaminase, alkaline phosphatase and bilirubin are monitored regularly following transplant, for early detection of hepatotoxicity. 
Pri zdravljenju takšnih bolnikov se zaradi zgodnjega odkrivanja hepatotoksičnosti priporoča redno spremljanje transaminaze, alkalne fosfataze in bilirubina v serumu po presaditvi.
Tell your doctor if you are taking, have recently taken or might take any other medicines. 
Obvestite svojega zdravnika, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
In pre-clinical studies thiotepa, as most alkylating agents, has been shown to cause embryofoetal lethality and teratogenicity (see section 5.3). 
Predklinične študije so pokazale, da tiotepa, kot večina alkilirajočih učinkovin, povzroča smrt zarodka in plodu in ima teratogene učinke (glejte poglavje 5.3).
During conversion of GSH conjugates to N-acetylcysteine conjugates, GSH, cysteinylglycine, and cysteine conjugates are formed. 
Med pretvorbo konjugatov GSH (growthstimulating hormone) v konjugate N-acetilcisteina se oblikujejo GSH, cisteinilglicin in konjugati cisteina.
Frequency of administration 
Pogostost uporabe
Name and address of the manufacturer(s) responsible for batch release 
Ime in naslov proizvajalca (proizvajalcev), odgovornega (odgovornih) za sproščanje serij RIEMSER Pharma GmbH
Procedures for proper handling and disposal of anticancer medicinal products must be considered. 
Upoštevati morate postopke za pravilno ravnanje in odstranjevanje zdravil proti raku.
20867 Caponago (MB) Italy Tel: +39-02 40700445 adienne@adienne.com 
20867 Caponago (MB) Italija Tel. +39-02 40700445 adienne@adienne.com
You must not use TEPADINA during pregnancy. 
Zdravila TEPADINA ne smete uporabljati med nosečnostjo.
Haematological diseases 
Hematološke bolezni
TEPADINA is unstable in acid medium. 
Zdravilo TEPADINA je nestabilno v kislem mediju.
Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) very rare (<1/10,000), not known (cannot be estimated from the available data). 
zelo pogosti (≥ 1/10), pogosti (≥1/100 do < 1/10), občasni (≥1/1.000 do < 1/100), redki (≥1/10.000 do < 1/1.000), zelo redki (< 1/10.000); neznani (ni mogoče oceniti iz razpoložljivih podatkov).
TEPADINA must be administered by a qualified healthcare professional as a 2-4 hours intravenous infusion via a central venous catheter. 
Zdravilo TEPADINA mora aplicirati usposobljen zdravstveni delavec, in sicer kot intravensko infuzijo po centralnem venskem katetru, ki traja 2 do 4 ure.
From a microbiological point of view, the product should be used immediately after dilution. 
Z mikrobiološkega stališča je treba zdravilo uporabiti takoj po redčenju.
Studies in renally impaired patients have not been conducted. 
Študije pri bolnikih z okvaro ledvic niso bile izvedene.
The administration of thiotepa has not been specifically investigated in elderly patients. 
Uporaba tiotepe pri starejših bolnikih ni bila posebej raziskana.
In some cases, relapse rates of 35% and of 45% have been reported at 5 years and 6 years respectively. 
V nekaterih primerih so za obdobji 5 in 6 let poročali o stopnjah ponovitve 35 oziroma 45 odstotkov.
Relapse: In all the reported conditioning regimens containing thiotepa, relapse rates at 12 to 57 months ranged from 33% to 57%. 
Ponovitev bolezni: pri vseh režimih pripravljalnega zdravljenja s tiotepo, o katerih so poročali, so bile stopnje ponovitve v obdobju 12 do 57 mesecev med 33 in 57 %.
Disease Free Survival (DFS): With a follow-up of 36 to 57 months, DFS ranged from 46% to 70% in the reported studies. 
Preživetje brez ponovitve bolezni : v obdobju 36 do 57 mesecev je bilo DFS med 46 in 70 % v študijah, o katerih so poročali.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than the above mentioned conditions when dilution has taken place in controlled and validated aseptic conditions. 
Običajno se redčeno zdravilo ne hrani dlje kot v zgoraj navedenih pogojih, ko je zdravilo redčeno v nadzorovanih in validiranih aseptičnih pogojih.
In allogeneic HPCT, the conditioning treatment must be sufficiently immunosuppressive and myeloablative to overcome host rejection of the graft. 
Pri alogenski PKMC mora biti pripravljalno zdravljenje zelo imunosupresivno in mieloablativno, da gostitelj ne zavrne presadka.
Precautions to be taken before handling or administering the medicinal product Topical reactions associated with accidental exposure to thiotepa may occur. 
Previdnostni ukrepi, potrebni pred ravnanjem z zdravilom ali dajanjem zdravila Lahko se pojavijo lokalne reakcije, povezane z nenamerno izpostavitvijo tiotepi.
As alkylating agent, thiotepa produces the most profound inhibition of tumour cell growth in vitro with the smallest increase in medicinal product concentration. 
Tiotepa kot alkilirajoča učinkovina najbolj učinkovito zavira rast tumorskih celic in vitro z majhnim povečanjem koncentracije zdravila.
Side effects of TEPADINA may occur with certain frequencies, which are defined as follows: 
Neželeni učinki zdravila TEPADINA se lahko pojavijo z določeno pogostnostjo, in sicer:
Regimen Related Mortality (RRM) and Transplant Related Mortality (TRM): low values have been reported, confirming the safety of the conditioning treatments including thiotepa for allogeneic HPCT in adult patients with haematological diseases. 
Z režimom povezana umrljivost in s presaditvijo povezana umrljivost: poročali so o nizkih vrednostih, kar potrjuje varnost pripravljalnih zdravljenj s tiotepo za alogensko PKMC pri odraslih bolnikih s hematološkimi boleznimi.
TEPADINA is administered by a qualified healthcare professional as an intravenous infusion (drip in a vein) after dilution of the individual vial. 
Zdravilo TEPADINA vam bo dal usposobljen zdravstveni delavec, in sicer v obliki intravenske infuzije (kapalne infuzije v veno) po razredčenju posamezne viale.
Therefore, a clinical monitoring should be exercised during the concomitant use of thiotepa and these medicinal products. 
Zato je treba bolnike pozorno klinično spremljati med sočasno uporabo tiotepe in teh zdravil.
Other medicines and TEPADINA 
Druga zdravila in zdravilo TEPADINA
Considering that all patients were treated for high risk solid tumours, DFS results confirm that conditioning treatments containing thiotepa following autologous HPCT are effective therapeutic strategies for treating paediatric patients with solid tumours. 
Ker so bili vsi bolniki zdravljeni zaradi čvrstih tumorjev z visokim tveganjem, rezultati potrjujejo, da so pripravljalna zdravljenja s tiotepo po avtologni PKMC učinkovite terapevtske strategije za zdravljenje pediatričnih bolnikov s čvrstimi tumorji.
TEPADINA must be delivered after the completion of any cyclophosphamide infusion (see section 4.5). 
Zdravilo TEPADINA je treba odmeriti po zaključku infundiranja ciklofosfamida (glejte poglavje 4.5).
Respiratory arrest 
- zastoj dihanja
Tabulated list of adverse reactions 
Tabelarični zapis neželenih učinkov
Co-administration with inhibitors of CYP2B6 (for example clopidogrel and ticlopidine) or CYP3A4 (for example azole antifungals, macrolides like erythromycin, clarithromycin, telithromycin, and protease inhibitors) may increase the plasma concentrations of thiotepa and potentially decrease the concentrations of the active metabolite TEPA. 
Sočasna uporaba z zaviralci CYP2B6 (na primer klopidogrelom in tiklopidinom) ali CYP3A4 (na primer azolni antimikotiki, makrolidi, kot so eritromicin, klaritromicin, telitromicin, ter zaviralci proteaz) lahko zviša koncentracijo tiotepe v plazmi in potencialno zniža koncentracije aktivnega presnovka tetraetilenpentamina (TEPA).
TEPADINA administration must be supervised by a physician experienced in conditioning treatment prior to haematopoietic progenitor cell transplantation. 
Uporabo zdravila TEPADINA mora nadzorovati zdravnik z izkušnjami na področju pripravljalnega zdravljenja pred presaditvijo krvotvornih matičnih celic.
TEPADINA is administered at different doses, in combination with other chemotherapeutic medicinal products, in patients with haematological diseases or solid tumours prior to HPCT. 
Zdravilo TEPADINA se uporablja v različnih odmerkih, v kombinaciji z drugimi kemoterapevtiki, pri bolnikih z hematološkimi boleznimi ali čvrstimi tumorji pred PKMC.
The concomitant use of thiotepa and other myelosuppressive or myelotoxic agents (i.e. cyclophosphamide, melphalan, busulfan, fludarabine, treosulfan) may potentiate the risk of haematologic adverse reactions due to overlapping toxicity profiles of these medicinal products. 
Sočasna uporaba tiotepe in drugih mielosupresivnih ali mielotoksičnih učinkovin (tj. ciklofosfamid, melfalan, busulfan, fludarabin, treosulfan) lahko poveča tveganje neželenih hematoloških učinkov zaradi prekrivajočih se profilov toksičnosti teh zdravil.
Contents of the pack and other information 
Shranjevanje zdravila TEPADINA Vsebina pakiranja in dodatne informacije
DFS results confirm that conditioning treatment containing thiotepa following allogeneic HPCT are effective therapeutic strategies for treating paediatric patients with haematological diseases. 
Rezultati DFS potrjujejo, da so pripravljalna zdravljenja s tiotepo po alogenski PKMC učinkovite terapevtske strategije za zdravljenje pediatričnih bolnikov s hematološkimi boleznimi.
After reconstitution and dilution 
Po rekonstituciji in redčenju
Co-administration of inducers of cytochrome P450 (such as rifampicin, carbamazepine, phenobarbital) may increase the metabolism of thiotepa leading to increased plasma concentrations of the active metabolite. 
Sočasna uporaba induktorjev citokroma P450 (kot so rifampicin, karbamazepin, fenobarbital) lahko zveča presnovo tiotepe, kar privede do zvišane koncentracije aktivnega presnovka v plazmi.
The adverse reactions considered at least possibly related to conditioning treatment including thiotepa, reported in adult patients as more than an isolated case, are listed below by system organ class and by frequency. 
Neželeni učinki, ki so vsaj potencialno povezani s pripravljalnim zdravljenjem, ki vključuje tiotepo, in o katerih so poročali pri odraslih bolnikih o več kot le o posameznem primeru, so navedeni spodaj glede na organski sistem in pogostnost.